Physician profile
Ashok Vs Kumar
NPI 1225030141
$17,979.90
in general payments reported to CMS, 2019-2025
74 companies · $3,305 in 2025
The $3,305 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $2,301 · 2021: $1,974 · 2022: $2,893 · 2023: $3,125 · 2024: $2,626 · 2025: $3,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,258 · Honoraria: $1,275 · Education: $491 · Travel and Lodging: $31.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,258.10 |
| Honoraria | $1,275.00 |
| Education | $491.02 |
| Travel and Lodging | $31.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $1,493.47 | 2021-2025 | Qinlock |
| Janssen Biotech, INC. | $1,252.86 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $1,158.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,054.74 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,004.01 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $859.10 | 2019-2025 | |
| Amgen INC. | $781.43 | 2019-2023 | Kyprolis, Lumakras |
| Genentech USA, INC. | $768.26 | 2019-2024 | Venclexta, Polivy, Phesgo |
| E.R. Squibb & Sons, L.L.C. | $699.35 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Seagen INC. | $634.30 | 2020-2025 | Tukysa, Adcetris |
| Celgene Corporation | $534.13 | 2019-2025 | Pomalyst, Reblozyl |
| Incyte Corporation | $531.62 | 2019-2024 | Jakafi |
| Genzyme Corporation | $488.47 | 2019-2025 | |
| Astellas Pharma US INC | $419.84 | 2020-2024 | Xospata, Padcev |
| Lilly USA, LLC | $366.21 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $328.91 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $311.07 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $300.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $274.20 | 2020-2024 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $251.43 | 2019-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $240.25 | 2022-2025 | Ninlaro, Iclusig, Alunbrig |
| Abbvie INC. | $213.35 | 2019-2025 | |
| Exelixis INC. | $211.17 | 2019-2024 | Cabometyx |
| Eisai INC. | $203.18 | 2019-2025 | |
| Kite Pharma, INC. | $192.41 | 2020-2023 | Yescarta |
| Adaptive Biotechnologies Corporation | $190.60 | 2022-2025 | Clonoseq |
| Emd Serono, INC. | $157.86 | 2020-2025 | Tepmetko, Bavencio |
| Foundation Medicine, INC. | $152.14 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $150.30 | 2022-2023 | Fotivda |
| Myriad Genetic Laboratories, INC. | $149.33 | 2021-2024 | Myrisk, Precisetumor |
| Tempus Ai, INC | $149.24 | 2024 | Xt Cdx |
| Array Biopharma INC | $148.42 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $146.60 | 2022-2025 | Monoferric |
| Pharmaessentia USA Corporation | $144.33 | 2022-2024 | Besremi |
| Ipsen Biopharmaceuticals, INC | $141.30 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Kyowa Kirin, INC. | $139.38 | 2019-2024 | Poteligeo |
| Sobi, INC | $133.14 | 2024-2025 | |
| Taiho Oncology, INC. | $115.82 | 2022-2024 | |
| Jazz Pharmaceuticals INC. | $110.31 | 2019-2025 | |
| Beigene USA, INC. | $100.05 | 2022-2023 | Brukinsa |
| Sirtex Medical INC | $97.68 | 2020-2022 | |
| Servier Pharmaceuticals LLC | $92.26 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $68.69 | 2022-2024 | Xpovio |
| Caris Mpi, INC. | $64.55 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $62.00 | 2023-2024 | Sylvant |
| Acceleron Pharma, INC. | $60.55 | 2021 | |
| Puma Biotechnology, INC. | $59.89 | 2019-2023 | |
| Agios Pharmaceuticals, INC. | $55.04 | 2024-2025 | Pyrukynd |
| Clovis Oncology, INC. | $54.36 | 2020-2022 | |
| Tersera Therapeutics LLC | $47.57 | 2022-2023 | Quzyttir |
| Advanced Accelerator Applications | $43.10 | 2019 | |
| Alexion Pharmaceuticals, INC. | $42.64 | 2022-2023 | Ultomiris |
| Adc Therapeutics America, INC. | $40.69 | 2021-2023 | |
| Cti Biopharma Corp. | $36.50 | 2022 | |
| Coherus Oncology, INC. | $35.60 | 2022 | |
| Amneal Pharmaceuticals LLC | $33.20 | 2023-2025 | Avastin, Alymsys |
| Teva Pharmaceuticals USA, INC. | $32.10 | 2020 | |
| Janssen Scientific Affairs, LLC | $27.31 | 2019 | |
| Ferring Pharmaceuticals INC. | $27.11 | 2024 | Adstiladrin |
| Gilead Sciences, INC. | $25.72 | 2019 | |
| Octapharma USA, INC. | $24.91 | 2020 | |
| Epizyme, INC. | $24.75 | 2022 | |
| Fennec Pharmaceuticals, INC. | $24.32 | 2024 | Pedmark |
| Dendreon Pharmaceuticals LLC | $23.15 | 2025 | Provenge |
| Dova Pharmaceuticals | $20.90 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $20.66 | 2019 | |
| Tolmar, INC. | $20.02 | 2024 | |
| Mylan Institutional INC. | $18.78 | 2022 | |
| Organon LLC | $17.93 | 2022 | |
| Blue Earth Diagnostics | $17.44 | 2024 | |
| Stemline Therapeutics INC. | $17.18 | 2024 | Orserdu |
| Lexicon Pharmaceuticals, INC. | $14.65 | 2019 | |
| Verastem, INC. | $13.72 | 2019 | |
| Secura Bio, INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.